TrialRMD open2025

Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial.

Hideto Kameda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.